The milestone payment strengthens VivoSim's cash position while management projects significant revenue growth driven by expanding demand for its human-based preclinical testing platform.
VivoSim (NASDAQ:VIVS) received a $5 million milestone payment from Eli Lilly tied to the advancement of a previously sold drug candidate into Phase 2 studies.
The company expects more than 500% revenue growth in fiscal 2027, reflecting increasing adoption of its NAM contract research services.
VivoSim remains eligible for up to $45 million in additional milestone payments if future regulatory and commercial milestones are achieved.
Management says demand is being supported by growing pharmaceutical interest in New Approach Methodologies (NAMs) and AI-enabled human tissue models.
VivoSim (NASDAQ:VIVS) received a $5 million milestone payment from Eli Lilly tied to the advancement of a previously sold drug candidate into Phase 2 studies.
The company expects more than 500% revenue growth in fiscal 2027, reflecting increasing adoption of its NAM contract research services.
VivoSim remains eligible for up to $45 million in additional milestone payments if future regulatory and commercial milestones are achieved.
Management says demand is being supported by growing pharmaceutical interest in New Approach Methodologies (NAMs) and AI-enabled human tissue models.
25 days ago
